Radiation Oncology

Main lines of research

Research is partially conducted on the premises of the Translational Research Laboratory of the Catalan Oncology Institute (ICO)-Bellvitge Biomedical Research Institute (IDIBELL) under a framework agreement between Sant Pau and the ICO.

Modulation of Radiosensitivity

  • Modulation of radiosensitivity by SRC protein inhibitors in combination with anti-EGFR.
  • Modulation of radiosensitivity by HMG-CoA reductase inhibitors in combination with anti-EGFR.

SBRT for Patients with Lung Cancer and with Oligometastases

  • Stereotactic body radiotherapy techniques in radical treatment of patients with early-stage non-surgical lung cancer and selected patients with non-surgical oligometastases.

Radiation Therapy Based on PET/CT Functional Imaging of Tumours

  • Implementation of planning techniques for radiotherapy treatment with PET/CT for chest locations and head and neck tumours squamous cell tumours.
  • Image-guided radiotherapy and respiratory movement control.
  • Salvage brachytherapy for local recurrence after external beam radiotherapy in prostate cancer.
  • Hypofractionated intensity-modulated GRT in prostate cancer.


  • Establish relatively radioresistant cell lines compared with the parental cells from which they derive (by clonal selection).
  • Determine the resistant phenotype in cultures and xenografts.
  • Determine molecular radioresistance.
  • Evaluate the effect on carcinomas of SRC and HMG-CoA reductase inhibitors in combination with anti-EGFR.
  • Explore signal transduction changes in the EGFR-MAPK pathway and SRC-EGFR/SRCSTAT3 cooperation induced by SRC and HMG-CoA reductase inhibitors.
This site is registered on as a development site.

Aquest lloc web utilitza cookies per millorar l'experiència de navegació i realitzar tasques analítiques. Si continues navegant, considerem que n’acceptes l’ús. Més informació